Kintayl Capital LP Takes Position in Penumbra, Inc. $PEN

Kintayl Capital LP purchased a new stake in shares of Penumbra, Inc. (NYSE:PEN) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 9,251 shares of the company’s stock, valued at approximately $2,921,000. Penumbra comprises about 1.2% of Kintayl Capital LP’s investment portfolio, making the stock its 26th biggest position.

A number of other institutional investors have also added to or reduced their stakes in the stock. Hsbc Holdings PLC boosted its position in Penumbra by 2.3% in the fourth quarter. Hsbc Holdings PLC now owns 1,527 shares of the company’s stock valued at $475,000 after buying an additional 35 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Penumbra by 27.1% in the 4th quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock valued at $55,000 after acquiring an additional 38 shares during the last quarter. Swiss Life Asset Management Ltd lifted its stake in shares of Penumbra by 2.3% in the 4th quarter. Swiss Life Asset Management Ltd now owns 1,728 shares of the company’s stock valued at $537,000 after acquiring an additional 39 shares during the last quarter. Keybank National Association OH boosted its holdings in shares of Penumbra by 1.2% during the 4th quarter. Keybank National Association OH now owns 3,705 shares of the company’s stock valued at $1,152,000 after acquiring an additional 43 shares in the last quarter. Finally, UMB Bank n.a. boosted its stake in shares of Penumbra by 11.3% during the fourth quarter. UMB Bank n.a. now owns 442 shares of the company’s stock valued at $137,000 after purchasing an additional 45 shares in the last quarter. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Penumbra Stock Up 0.3%

Penumbra stock opened at $324.61 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.86 and a current ratio of 5.75. Penumbra, Inc. has a 52-week low of $221.26 and a 52-week high of $362.41. The firm has a 50 day moving average price of $320.38 and a two-hundred day moving average price of $327.16. The firm has a market cap of $12.79 billion, a price-to-earnings ratio of 79.76, a PEG ratio of 2.01 and a beta of 0.70.

Penumbra (NYSE:PEN) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.88 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.28). Penumbra had a net margin of 10.67% and a return on equity of 10.50%. The firm had revenue of $390.05 million during the quarter, compared to the consensus estimate of $389.64 million. During the same period in the prior year, the company posted $0.86 earnings per share. The company’s revenue for the quarter was up 14.9% compared to the same quarter last year. Equities analysts predict that Penumbra, Inc. will post 5.02 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Evercore reiterated an “outperform” rating and set a $320.00 target price on shares of Penumbra in a research report on Monday, July 6th. Weiss Ratings restated a “hold (c)” rating on shares of Penumbra in a research report on Friday, July 17th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $374.00 price target on shares of Penumbra in a research note on Thursday, June 11th. Zacks Research lowered shares of Penumbra from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Finally, Citigroup reduced their price objective on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating on the stock in a research note on Thursday, May 7th. Three research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $367.07.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.